Plasma phospho-tau217 as a predictive biomarker for Alzheimer’s disease in a large south American cohort

Plasma phospho-tau217 as a predictive biomarker for Alzheimer’s disease in a large south American cohort

Abstract Background Blood-based Alzheimer’s disease (AD) biomarkers have been increasingly employed for diagnostic, prognostic, and therapeutic monitoring purposes, due to accuracy in distinguishing AD pathophysiologic process. Compared to other p-tau isoforms, plasma p-tau217 exhibits stronger asso...

Full description

Saved in:

Bibliographic Details
Main Authors:	Neetesh Pandey, Zikun Yang, Basilio Cieza, Dolly Reyes-Dumeyer, Min Suk Kang, Rosa Montesinos, Marcio Soto-Añari, Nilton Custodio, Lawrence S. Honig, Giuseppe Tosto
Format:	Article
Language:	English
Published:	BMC 2025-01-01
Series:	Alzheimer’s Research & Therapy
Subjects:	Alzheimer’s disease Plasma biomarker P-tau217 Plasma APOE
Online Access:	https://doi.org/10.1186/s13195-024-01655-w
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Identification of late-stage tau accumulation using plasma phospho-tau217Research in context
by: Marcel S. Woo, et al.
Published: (2024-11-01)

Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217
by: Branislav Kovacech, et al.
Published: (2024-11-01)

Longitudinal trajectory of plasma p-tau217 in cognitively unimpaired subjects
by: Francisco Martínez-Dubarbie, et al.
Published: (2024-12-01)

Detection and staging of Alzheimer's disease by plasma pTau217 on a high throughput immunoassay platformResearch in context
by: Azadeh Feizpour, et al.
Published: (2024-11-01)

Comparison of plasma p-tau217 and p-tau181 in predicting amyloid positivity and prognosis among Korean memory clinic patients
by: Hyuk Sung Kwon, et al.
Published: (2025-03-01)

The two cut‐offs approach for plasma p‐tau217 in detecting Alzheimer's disease in subjective cognitive decline and mild cognitive impairment
by: Giulia Giacomucci, et al.
Published: (2025-04-01)

Plasma phosphorylated tau 217 and amyloid‑β 42/40 for amyloid risk in subgroups
by: Heekyoung Kang, et al.
Published: (2025-08-01)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
by: Niklas Mattsson‐Carlgren, et al.
Published: (2021-05-01)

Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platform
by: Francisco Martínez-Dubarbie, et al.
Published: (2025-03-01)

Analytical and clinical validation of a high accuracy fully automated digital immunoassay for plasma phospho-Tau 217 for clinical use in detecting amyloid pathology
by: David Wilson, et al.
Published: (2025-07-01)

Clinical decision points for two plasma p‐tau217 laboratory developed tests in neuropathology confirmed samples
by: Anna E. Mammel, et al.
Published: (2025-01-01)

A novel pThr217 tau monoclonal antibody reveals neuropathological heterogeneity in tauopathies
by: Giavanna Paterno, et al.
Published: (2025-06-01)

Detecting amyloid and tau pathology in Parkinson’s disease, 4R-tauopathies and control subjects with plasma pTau217
by: Giulia Musso, et al.
Published: (2025-08-01)

Exploring the association between mild behavioral impairment and plasma p‐tau217: Implications for early detection of Alzheimer's disease
by: Maryam Ghahremani, et al.
Published: (2025-04-01)

Early cerebrospinal fluid elevations of pTau-217 in severe traumatic brain injury subjects
by: Hamad Yadikar, et al.
Published: (2025-07-01)

Clinical and neuropathological associations of plasma Aβ42/Aβ40, p‐tau217 and neurofilament light in sporadic frontotemporal dementia spectrum disorders
by: Binita Rajbanshi, et al.
Published: (2025-01-01)

Analytical and clinical performance of eight Simoa® and Lumipulse® assays for automated measurement of plasma p-tau181 and p-tau217
by: Anna L. Wojdała, et al.
Published: (2024-12-01)

Clinical performance of the fully automated Lumipulse plasma p‐tau217 assay in mild cognitive impairment and mild dementia
by: Adam H. Dyer, et al.
Published: (2025-01-01)

Plasma biomarkers for early detection of alzheimer’s disease: a cross-sectional study in a Japanese cohort
by: Masahito Kubota, et al.
Published: (2025-06-01)

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected
by: Marc Suárez‐Calvet, et al.
Published: (2020-11-01)

Development and Validation of the HPLC Method for Quantification of the Innovative Drug DD217, Factor Xa Inhibitor, in Rat Plasma for a Pharmacokinetic Study
by: N. S. Dubovik, et al.
Published: (2022-05-01)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
by: Rik Ossenkoppele, et al.
Published: (2021-07-01)

Optimizing timing and cost-effective use of plasma biomarkers in Alzheimer’s disease
by: Hsin-I Chang, et al.
Published: (2025-08-01)

Comparison of plasma ALZpath p-Tau217 with Lilly p-Tau217 and p-Tau181 in a neuropathological cohort
by: Divya Bali, et al.
Published: (2025-06-01)

Testing the causal impact of plasma amyloid on total Tau using a genetically informative sample of adult male twins
by: Nathan A. Gillespie, et al.
Published: (2025-01-01)

Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort
by: Menayit Tamrat Dresse, et al.
Published: (2025-07-01)

TOMM40 may mediate GFAP, neurofilament light Protein, pTau181, and brain morphometry in aging
by: Robyn A. Honea, et al.
Published: (2025-01-01)

Resistance and resilience to tau pathology in Alzheimer's disease: Effects of age, sex, and APOE alleles
by: Yury Loika, et al.
Published: (2024-10-01)

Prospective evaluation of plasma pTau217 stability for the detection of Alzheimer’s disease in a tertiary memory clinic
by: Javier Arranz, et al.
Published: (2025-07-01)

Clinical and demographic factors modify the association between plasma phosphorylated tau‐181 and cognition
by: Corey J. Bolton, et al.
Published: (2024-10-01)

Cross‐sectional study of plasma phosphorylated tau 217 in persons without dementia
by: Toni T. Saari, et al.
Published: (2025-04-01)

Semantic intrusion errors differentiate between amnestic MCI who are plasma p-tau217+ from p-tau217- after adjusting for initial learning strength
by: Rosie E. Curiel Cid, et al.
Published: (2025-07-01)

Biochemical analysis of miR-217 and miR-532 in patients with fibromyalgia
by: Shymaa E. Ayoub, et al.
Published: (2025-02-01)

Phospho-tau 181 is enhanced in saliva and plasma of edentulous patients: a first sign of dementia?
by: Christine Zürcher, et al.
Published: (2025-07-01)

Chronic RNA G-quadruplex accumulation in aging and Alzheimer’s disease
by: Lena Kallweit, et al.
Published: (2025-02-01)

Contributions of major tau kinase activation and phospho-tau accumulation to cortical and hippocampal tangle formation and cognition in older adults
by: Elena Hernández-Hernández, et al.
Published: (2025-06-01)

TRPV1 alleviates APOE4-dependent microglial antigen presentation and T cell infiltration in Alzheimer's disease
by: Jia Lu, et al.
Published: (2024-10-01)

Assoclation polymorphism apoe gene and blood lipid profile with diffe different types of stroke in Siberia
by: M. I. Voevoda, et al.
Published: (2011-04-01)

Exploring the ability of plasma pTau217, pTau181 and beta-amyloid in mirroring cerebrospinal fluid biomarker profile of Mild Cognitive Impairment by the fully automated Lumipulse® platform
by: Marcella Catania, et al.
Published: (2025-01-01)

Cerebrospinal fluid sTREM2 mediates the associations of α-synuclein with tau pathology in older adults without dementia: two population-based study
by: Yong-Chang Wang, et al.
Published: (2025-07-01)